Clinical Trial Update: TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating TCRαβ-depleted progenitor cell graft with added memory T-cell donor lymphocyte infusion and selective use of blinatumom…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Chronic Myeloid Leukemia
• Hodgkin Lymphoma
• Juvenile Myelomonocytic Leukemia
• Myelodysplastic Syndromes
• Natural Killer Cell Leukemia
• Non-hodgkin Lymphoma

Drugs mentioned

• Blinatumomab (blinatumomab)
• Memory T-cell donor lymphocyte infusion (memory T-cell donor lymphocyte infusion)
• TCRαβ-depleted progenitor cell graft

Snippet

Sponsor: St. Jude Children's Research Hospital | Conditions: Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML) | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2026-03-04